Hepatitis C
Conditions
Keywords
Hepatitis C, primary care
Brief summary
The Prime Study is a randomised trial investigating models of care for hepatitis C in the era of direct acting antiviral (DAA) therapy. The study aims to compare outcomes of hepatitis C care and DAA treatment provided in a primary health care service with a tertiary hospital.
Detailed description
This open label randomised trial will investigate the efficacy of treating people with G1 HCV with DAA in primary healthcare services compared with tertiary hospital clinics. Three hundred and eighty G1 HCV infected patients attending study primary healthcare centres will be invited to participate in the study. At the primary healthcare centre participants will be randomly allocated to two groups: Group 1: (n=190) Following their initial screen, these participants will be referred to a tertiary hospital for transient elastography and DAA treatment (traditional model of care) Group 2: (n=190) Following their initial screen, these participants will be offered transient elastography and DAA treatment delivered at the primary healthcare service only. Treatment will consist of fixed dose combination paritaprevir, ombitasvir and ritonavir packaged together with dasabuvir, known as Viekira Pak, +/- weight based ribavirin. As cirrhotic patients will be excluded from the study, the duration of treatment is 12 weeks.
Interventions
OTHERcommunity based hepatitis C care and treatment
Sponsors
St Vincent's Hospital Melbourne
Macfarlane Burnet Institute for Medical Research and Public Health Ltd
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Aged ≥18 years; * Attendance at a study PHCS defined as; Attended appointment at PHCS at least once in 2014 or; Attended at least one consultation with a study community hepatitis nurse between 2012-2014 * Evidence of chronic G1 HCV infection (HCV antibody positive for \> 6 months and HCV RNA positive); * Absence of cirrhosis defined as one of the following: Liver biopsy within 24 months prior to screening demonstrating absence of cirrhosis (e.g. a Metavir score of 3 or less or an Ishak score of 4 or less); or A screening FibroScan result of \<9.6 kPa; or if a FibroScan is unsuccessful A screening Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤ 2 and no clinical or laboratory evidence of cirrhosis; * HCV treatment naive or pegylated or standard interferon and ribavirin experienced; * Willing and able to provide written informed consent Subjects must have the following laboratory parameters at screening: * ALT ≤ 10 times the upper limit of normal (ULN); * AST ≤ 10 times ULN * Haemoglobin ≥ 12g/dL for males; ≥ 11g/dL for female subjects; * Platelet count ≥ laboratory lower limit of normal; * INR ≤ laboratory upper limit of normal, unless stable on an anticoagulant regimen affecting INR; * Albumin ≥ laboratory lower limit of normal; * Direct bilirubin ≤ laboratory upper limit of normal; * Creatinine clearance (Clcr) ≥ 60mL/min as calculated by Cockcroft-Gault equation.
Exclusion criteria
* Known cirrhosis defined as: Liver biopsy within 24 months prior to screening demonstrating cirrhosis (e.g. a Metavir score \> 3 or an Ishak score \> 4); or A FibroScan result of \>12.5 kPa; or Prior clinical evidence of cirrhosis or portal hypertension (i.e. ascites, varices). * Prior exposure to HCV DAA protease inhibitors * Currently receiving HCV treatment; * Testing positive for HIV; * Testing positive for HBsAg; * HCC; * Pregnancy or breastfeeding at screening or baseline; * Evidence of any condition, therapy, laboratory abnormality or other circumstance (current or prior) that may confound the study's results, or interfere with participation for the full duration of the study, such that it is not in the best interest of the participant; * Use of concomitant medications that are contraindicated with Viekira Pak within 28 days of the baseline/day 1 visit, that are unable to be ceased for the duration of treatment. Additional
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To measure the proportion of people attending at a Primary Health Care Service for their genotype 1 HCV infection who commence antiviral treatment (Viekira Pak and ribavirin) and have a SVR 12. | Sustained virology response (SVR) rates at week 12 post treatment. |
Secondary
| Measure | Time frame |
|---|---|
| To measure the proportion of people attending a PHCS with G1 HCV infection who commence antiviral treatment (Viekira Pak and ribavirin) if they are managed at a PHCS compared to those who are referred to and managed at a tertiary hospital. | Treatment uptake within 8 weeks of randomisation |
| To measure the proportion of people with G1 HCV who have an SVR12 at a PHCS compared a tertiary hospital. | SVR rate at week 12 post treatment |
| To measure the reduction in HCV viraemia (community viral load) among participants considering retention through the cascade of care and SVR12. | up to 24 weeks post treatment |
| To measure the cost effectiveness of managing and treating people in a primary health service compared to a tertiary hospital. | up to 24 weeks post treatment |
| To define the cascade of care for patients referred to a community hepatitis nurse for assessment of HCV. | up to 12 weeks post treatment |
Countries
Australia, New Zealand
Outcome results
None listed